pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

4,164 catalysts · 3,189 8k filing · 577 earnings · 172 phase 2 completion · 138 grant · 133 drug shortage · 89 approval

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 0 catalysts2026-08-12: 82 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 3 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2026-04-10×clear all
type
  • 8k filing3,189
  • earnings577
  • phase 2 completion172
  • grant138
  • drug shortage133
  • approval89
  • phase 1 completion73
  • phase 2 initiation62
  • phase 1 initiation40
  • recall37
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 20, 2026

    14
    ›Apr 26, 2026phase 2 results109d agoAllogene Therapeutics Inc — ALLO-647 (Phase II Trial Results)ALLO-647

    Therapy area: Oncology. Indication: Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma

    full page →ALLO-647 →source: globaldata
    ›Apr 26, 2026phase 2 results109d agoMinistero dell'Istruzione dell'Universita e della Ricerca — Bergacyn (Phase II Trial Results)Bergacyn

    Therapy area: Gastrointestinal. Indication: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)

    full page →Bergacyn →source: globaldata
    ›Apr 26, 2026phase 2 results109d agoMinistry of Education University and Research, Italy — artichoke (Phase II Trial Results)artichoke

    Therapy area: Cardiovascular, Gastrointestinal. Indication: Endothelial Dysfunction, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)

    full page →artichoke →source: globaldata
    ›Apr 26, 2026phase 2 3 completion109d agoKasturba Medical College — dexmedetomidine (Phase II/III Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System. Indication: Sedation

    full page →dexmedetomidine →source: globaldata
    ›Apr 26, 2026phase 2 3 completion109d agoAll India Institute of Medical Sciences — progesterone (Phase II/III Trial Completion)PROGESTERONE

    Therapy area: Women's Health. Indication: Female Infertility

    full page →PROGESTERONE →source: globaldata
    ›Apr 26, 2026phase 3 completion109d agoBharatiya Sanskriti Darshan Trust — ayurvedic medicine (Phase III Trial Completion)ayurvedic medicine

    Therapy area: Metabolic Disorders. Indication: Type 2 Diabetes

    full page →ayurvedic medicine →source: globaldata
    ›Apr 26, 2026phase 3 completion109d agoHomi Bhabha Cancer Hospital Research Centre — megestrol (Phase III Trial Completion)megestrol

    Therapy area: Central Nervous System, Gastrointestinal, Genito Urinary System, Respiratory. Indication: Anorexia Nervosa, Unspecified Gastrointestinal Disorders, Unspecified Genito Urinary Disorders, Unspecified Respiratory Disorders

    full page →megestrol →source: globaldata
    ›Apr 26, 2026phase 3 completion109d agoHubei Provincial Center for Disease Control and Prevention — rabies vaccine (Phase III Trial Completion)rabies vaccine

    Therapy area: Infectious Disease. Indication: Rabies

    full page →rabies vaccine →source: globaldata
    ›Apr 26, 2026phase 3 completion109d agoTehran University of Medical Sciences — diltiazem (Phase III Trial Completion)diltiazem

    Therapy area: Cardiovascular. Indication: Unspecified Cardiovascular Disorders

    full page →diltiazem →source: globaldata
    ›Apr 26, 2026phase 3 initiation109d agoStanford University — zanubrutinib (Phase III Trial Initiation)zanubrutinib

    Therapy area: Immunology. Indication: Immunoglobulin G4-Related Disease (IgG4-RD)

    full page →zanubrutinib →source: globaldata
    ›Apr 26, 2026phase iii iv trial completion109d agoRajaRajeswari Medical College & Hospital — stromal vascular fraction (Phase III/IV Trial Completion)stromal vascular fraction

    Therapy area: Dermatology. Indication: Androgenic Alopecia

    full page →stromal vascular fraction →source: globaldata
    ›Apr 26, 2026phase iii iv trial completion109d agoRanjeet Deshmukh Dental college and Research Center — clonidine (Phase III/IV Trial Completion)clonidine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →clonidine →source: globaldata
    ›Apr 26, 2026phase iv trial initiation109d agoKalpana Chawla Government Medical College — fentanyl (Phase IV Trial Initiation)fentanyl ER

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →fentanyl ER →source: globaldata
    ›Apr 26, 2026regulatory approval eu109d agoMinoryx Therapeutics sl — leriglitazone hydrochloride (Regulatory Approval (EU))leriglitazone hydrochloride

    Therapy area: Metabolic Disorders. Indication: Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD))

    full page →leriglitazone hydrochloride →source: globaldata

    Week of Apr 27, 2026

    36
    ›Apr 27, 2026phase 1 initiation108d agoNational Institute of Neurological Disorders and Stroke — pembrolizumab (Phase I Trial Initiation)pembrolizumab

    Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19), Post-Acute Sequelae of COVID 2019 (PASC or Long COVID)

    full page →pembrolizumab →source: globaldata
    ›Apr 27, 2026constraining patent expiry europe
    ← prev
    page 13 of 84
    next →
    108d ago
    Bill & Melinda Gates Medical Research Institute — SB-692342 (Constraining Patent Expiry (Europe))SB-692342

    Therapy area: Infectious Disease. Indication: Pulmonary Tuberculosis

    full page →SB-692342 →source: globaldata
    ›Apr 27, 2026patent expiry108d agoBill & Melinda Gates Medical Research Institute — SB-692342 (Constraining Patent Expiry (Japan))SB-692342

    Therapy area: Infectious Disease. Indication: Pulmonary Tuberculosis

    full page →SB-692342 →source: globaldata
    ›Apr 27, 2026pdufa108d agoRegeneron Pharmaceuticals Inc — dupilumab (PDUFA)dupilumab

    Therapy area: Dermatology. Indication: Chronic Urticaria

    full page →dupilumab →source: globaldata
    ›Apr 27, 2026phase 1 completion108d agoCTI Clinical Trial and Consulting Services Australia Pty Ltd — PTC-844 (Phase I Trial Completion)PTC-844

    Therapy area: Immunology. Indication: Unspecified Immunological Disorders

    full page →PTC-844 →source: globaldata
    ›Apr 27, 2026phase 1 completion108d agoFortrea Holdings Inc — balinatunfib (Phase I Trial Completion)balinatunfib

    Therapy area: Gastrointestinal, Immunology. Indication: Crohn's Disease (Regional Enteritis), Inflammatory Bowel Disease, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Ulcerative Colitis

    full page →balinatunfib →source: globaldata
    ›Apr 27, 2026phase 1 completion108d agoActimus Biosciences Pvt Ltd — ferric carboxymaltose (Phase I Trial Completion)ferric carboxymaltose

    Therapy area: Hematological Disorders. Indication: Iron Deficiency Anemia

    full page →ferric carboxymaltose →source: globaldata
    ›Apr 27, 2026phase 1 initiation108d agoNational Heart Lung and Blood Institute — fostamatinib (Phase I Trial Initiation)fostamatinib

    Therapy area: Immunology. Indication: Liver Transplant Rejection

    full page →fostamatinib →source: globaldata
    ›Apr 27, 2026phase 1 initiation108d agoCity of Hope — CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone] (Phase I Trial Initiation)CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone]

    Therapy area: Oncology. Indication: Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Follicular Lymphoma, Natural Killer Cell Lymphomas, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), T-Cell Lymphomas

    full page →CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone] →source: globaldata
    ›Apr 27, 2026phase 1 initiation108d agoNational Cancer Institute US — Autologous B7-H3 CAR T (Phase I Trial Initiation)Autologous B7-H3 CAR T

    Therapy area: Oncology. Indication: Neuroendocrine Cancer, Small-Cell Lung Cancer, Solid Tumor

    full page →Autologous B7-H3 CAR T →source: globaldata
    ›Apr 27, 2026phase 1 initiation108d agoHelixon — HXN-6005 (Phase I Trial Initiation)HXN-6005

    Therapy area: Undisclosed. Indication: Unspecified

    full page →HXN-6005 →source: globaldata
    ›Apr 27, 2026phase 1 initiation108d agoBrainBees Solutions Ltd — Babyhug pro soothing relief diaper rash cream (Phase I Trial Initiation)Babyhug pro soothing relief diaper rash cream

    Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

    full page →Babyhug pro soothing relief diaper rash cream →source: globaldata
    ›Apr 27, 2026phase 1 initiation108d agoArdi Farma Ilac Pazarlama Tic Ltd — clozapine (Phase I Trial Initiation)clozapine

    Therapy area: Central Nervous System. Indication: Schizophrenia, Unspecified Neurologic Disorders

    full page →clozapine →source: globaldata
    ›Apr 27, 2026phase 1 2 completion108d agoKLE Ayurveda Hospital — ayurvedic medicine (Phase I/II Trial Completion)ayurvedic medicine

    Therapy area: Central Nervous System, Gastrointestinal. Indication: Anorectal Disease, Post-Operative Pain

    full page →ayurvedic medicine →source: globaldata
    ›Apr 27, 2026phase 1 2 initiation108d agoNational Institutes of Health Clinical Center — azacitidine (Phase I/II Trial Initiation)Onureg

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma

    full page →Onureg →source: globaldata
    ›Apr 27, 2026phase 1 2 initiation108d agoThe National Institute of Diabetes and Digestive and Kidney Diseases — EBTATE (Phase I/II Trial Initiation)EBTATE

    Therapy area: Oncology. Indication: Thyroid Cancer

    full page →EBTATE →source: globaldata
    ›Apr 27, 2026phase 1 2 initiation108d agoNational Cancer Institute US — sacituzumab govitecan (Phase I/II Trial Initiation)sacituzumab govitecan

    Therapy area: Oncology. Indication: Neuroendocrine Cancer, Neuroendocrine Carcinoma, Small-Cell Lung Cancer

    full page →sacituzumab govitecan →source: globaldata
    ›Apr 27, 2026phase 2 completion108d agoSustained Therapeutics Inc — lidocaine SR (Phase II Trial Completion)LIDOCAINE

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →LIDOCAINE →source: globaldata
    ›Apr 27, 2026phase 2 completion108d agoSMBT Ayurved College and Hospital — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

    Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye)

    full page →ayurvedic medicine →source: globaldata
    ›Apr 27, 2026phase 2 completion108d agoChacha Nehru Bal Chikitsalaya — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 27, 2026phase 2 completion108d agoEuropean and Developing Countries Clinical Trials Partnership — (diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine (Phase II Trial Completion)(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine

    Therapy area: Infectious Disease. Indication: Salmonella Infections

    full page →(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine →source: globaldata
    ›Apr 27, 2026phase 2 completion108d agoOrthomedico Inc — lactococcus lactis subsp. cremoris YRC3780 (Phase II Trial Completion)lactococcus lactis subsp. cremoris YRC3780

    Therapy area: Central Nervous System. Indication: Sleep Disorders

    full page →lactococcus lactis subsp. cremoris YRC3780 →source: globaldata
    ›Apr 27, 2026phase 2 completion108d agoPt.Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences Rohtak — nivolumab (Phase II Trial Completion)nivolumab

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Squamous Non-Small Cell Lung Cancer

    full page →nivolumab →source: globaldata
    ›Apr 27, 2026phase 2 completion108d agoChina Red Cross Foundation — sufentanil (Phase II Trial Completion)sufentanil

    Therapy area: Gastrointestinal, Genito Urinary System. Indication: Hernia, Urinary Retention

    full page →sufentanil →source: globaldata
    ›Apr 27, 2026phase 2 completion108d agoKonya City Hospital — fentanyl (Phase II Trial Completion)fentanyl ER

    Therapy area: Central Nervous System, Gastrointestinal. Indication: Post-Operative Pain, Postoperative Ileus

    full page →fentanyl ER →source: globaldata
    ›Apr 27, 2026phase 2 completion108d agoBC Children's Hospital Research Institute — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Central Nervous System, Gastrointestinal. Indication: Appendicitis, Post-Operative Pain

    full page →dexamethasone →source: globaldata
    ›Apr 27, 2026phase 2 initiation108d agoTianjin Lisheng Pharmaceutical Co Ltd — aminophylline (Phase II Trial Initiation)aminophylline

    Therapy area: Cardiovascular, Respiratory. Indication: Asthma, Bronchitis, Emphysema, Pulmonary Edema

    full page →aminophylline →source: globaldata
    ›Apr 27, 2026phase 2 initiation108d agoShanghai Henlius Biotech Inc — HLX-35 (Phase II Trial Initiation)HLX-35

    Therapy area: Oncology. Indication: Solid Tumor, Squamous Non-Small Cell Lung Cancer

    full page →HLX-35 →source: globaldata
    ›Apr 27, 2026phase 2 initiation108d agoAnkara Etlik City Hospital — bupivacaine (Phase II Trial Initiation)bupivacaine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 27, 2026phase 2 initiation108d agoBrainBees Solutions Ltd — Babyhug pro soothing relief diaper rash cream (Phase II Trial Initiation)Babyhug pro soothing relief diaper rash cream

    Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

    full page →Babyhug pro soothing relief diaper rash cream →source: globaldata
    ›Apr 27, 2026phase 2 initiation108d agoMahatma Gandhi Medical College and Hospital — rosuvastatin (Phase II Trial Initiation)rosuvastatin

    Therapy area: Cardiovascular. Indication: Acute Coronary Syndrome, Myocardial Infarction

    full page →rosuvastatin →source: globaldata
    ›Apr 27, 2026phase 2 initiation108d agoJiangsu Hengrui Pharmaceuticals Co Ltd — HRS-3738 (Phase II Trial Initiation)HRS-3738

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →HRS-3738 →source: globaldata
    ›Apr 27, 2026phase 2 initiation108d agoYichun Maternal and Child health Care Hospital — sufentanil (Phase II Trial Initiation)sufentanil

    Therapy area: Central Nervous System, Women's Health. Indication: Labor And Delivery, Pain

    full page →sufentanil →source: globaldata
    ›Apr 27, 2026phase 2 initiation108d agoTilman SA — turmeric rhizome dry extract (Curcuma longa) (Phase II Trial Initiation)turmeric rhizome dry extract (Curcuma longa)

    Therapy area: Undisclosed. Indication: Unspecified

    full page →turmeric rhizome dry extract (Curcuma longa) →source: globaldata
    ›Apr 27, 2026phase 2 initiation108d agoWeifang Yidu Central Hospital — liposome bupivacaine (Phase II Trial Initiation)liposome bupivacaine

    Therapy area: Oncology. Indication: Lung Cancer

    full page →liposome bupivacaine →source: globaldata
    ›Apr 27, 2026phase 2 initiation108d agoNational Cancer Institute US — busulfan (Phase II Trial Initiation)busulfan

    Therapy area: Oncology. Indication: Blood Cancer, Hematological Tumor, Leukemia, Lymphoma

    full page →busulfan →source: globaldata
    $ALLO2.0701-2.35%
    $FTRE18.43-5.58%
    $REGN799.43+0.30%